In addition, we continue to expand the development of our lead program CB-010 into lupus and activation activities at multiple sites are underway as we plan to initiate our Phase 1 GALLOP trial by the ...

Caribou Biosciences (NASDAQ:CRBU) stock tumbled 30% Monday amid the release of Phase 1 data from its ANTLER study for the company’s CART-T cell therapy CB-010. The company said in a statement ...

Dr. Laufer is a leading rheumatologist known for her extensive research into immune cell regulation and dysfunction that leads to aut -- CB-010 allogeneic CAR-T cell therapy with partial HLA ...

In addition, we continue to expand the development of our lead program CB-010 into lupus and activation activities at multiple sites are underway as we plan to initiate our Phase 1 GALLOP trial by ...